A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Public ClinicalTrials.gov record NCT06572384. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
Study identification
- NCT ID
- NCT06572384
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 440 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2024
- Primary completion
- Oct 17, 2028
- Completion
- Dec 12, 2028
- Last update posted
- Mar 2, 2026
2024 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Los Angeles | California | 90033 | Recruiting |
| GSK Investigational Site | Los Angeles | California | 90095 | Recruiting |
| GSK Investigational Site | Los Angeles | California | 92868 | Recruiting |
| GSK Investigational Site | San Francisco | California | 94143 | Recruiting |
| GSK Investigational Site | Upland | California | 91786 | Recruiting |
| GSK Investigational Site | Gainesville | Florida | 32608 | Recruiting |
| GSK Investigational Site | Naples | Florida | 34102 | Recruiting |
| GSK Investigational Site | St Louis | Missouri | 63110 | Recruiting |
| GSK Investigational Site | New York | New York | 10029 | Recruiting |
| GSK Investigational Site | New York | New York | 10032 | Recruiting |
| GSK Investigational Site | Potsdam | New York | 13676 | Recruiting |
| GSK Investigational Site | Durham | North Carolina | 27710 | Recruiting |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77030 | Recruiting |
| GSK Investigational Site | Temple | Texas | 76508 | Recruiting |
| GSK Investigational Site | Salt Lake City | Utah | 84108 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06572384, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06572384 live on ClinicalTrials.gov.